The OcuPro headset records and analyses pupil characteristics to determine whether someone is impaired from recent cannabis use. Credit: WhyNotChannel via Shutterstock.

US-based company Oculogica announced the launch of a roadside cannabis test that records and analyses eye-pupil characteristics.

The OcuPro headset records and analyses pupil characteristics to determine whether someone is impaired from recent cannabis use. The device will be piloted across several police departments in Missouri, US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Current cannabis tests rely on analysing tetrahydrocannabinol (THC) from samples of urine, saliva, or blood.

Although active cannabis ingredient THC can remain in the body for months, it is long after the subject feels any effects of impairment.

OcuPro differentiates between recent use within 60-90 minutes versus use over several hours ago. Oculogica CEO Dr Rosina Samadani says that the product addresses an unmet need for a scientifically and clinically validated test for impairment from recent cannabis use.

Driving under the influence of cannabis is illegal, with the drug slowing reaction time, impairing coordination and decision-making, and distorting perception.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oculogica has performed clinical trials on cannabis users and non-users to develop technology that is able to differentiate between recent cannabis users and non-recent users.

Known for its eye-tracking technology, Oculogica aims to have the available devices available later this year, depending on the success of the pilot scheme.

Kansas City DUI Section Supervisor Sgt Blake Brownlee says: “In a legalised cannabis environment, we are in real need of a device that detects recent usage of cannabis, and impairment assessment would be ideal.”

Last year, Oculogica’s lead product EyeBOX has been granted clearance by US Food and Drug Administration (FDA). The device can non-invasively aid the diagnosis of concussion by measuring abnormalities in eye movements.

According to the company, it is the first FDA-cleared concussion diagnostic tool that does not require a pre-injury baseline.